NEW OPTION FOR MANAGEMENT OF HIGH-RISK SOFT TISSUE SARCOMA OF THE LIMB International, multi-centre sarcoma trial shows benefits of integrating immunotherapy with radiotherapy and surgery
The Australia and New Zealand Sarcoma Association (ANZSA) is the peak body for the sarcoma community. ANZSA aims to improve outcomes for sarcoma patients through research, education and awareness of sarcomas and related tumours.
ANZSA fosters effective collaborations across multi-disciplinary teams (MDT), which comprise of specialist health professionals (including pathologists, radiologists, surgeons, radiation oncologists, medical oncologists and paediatric oncologists) working together to discuss sarcoma and related tumours cases, and how to best manage treatment and care.
Professor Angela Hong MBBS, MMed, PhD, FRANZCR is the co-Chair of ANZSA’s Scientific Advisory Committee and a Professor at Sydney Medical School of the University of Sydney. She is a radiation oncologist and has been a member of the Multidisciplinary Bone and Soft Tissue Tumour Clinic at Royal Prince Alfred Hospital/Chris O’Brien Lifehouse for the past 15 years.
As a clinician scientist, her research focuses on developing innovative radiation therapy technique and combination treatments to improve the outcome for patients with sarcoma.
Professor Hong spoke to Australian Health Journal about sarcoma and a recently concluded international, multicentre trial, that could lead to a new potential option for patients grappling with high-risk sarcoma of the limb.
Soft tissue sarcoma, a rare aggressive cancer originating in connective tissues, can affect both children and adults. It is particularly challenging to conduct clinical trials due to its rarity, However a recently concluded international collaborative Phase II clinical trial SARC032 has shown groundbreaking findings into the advantages of Immunotherapy for patients with high-risk soft tissue sarcoma of the limb
The trial was led by the Sarcoma Alliance Research Collaboration (SARC) in the United States and the Australia and New Zealand Sarcoma Association (ANZSA) in Australia. The Australian participating sites in the trial were Peter MacCallum Cancer Centre, Chris O’Brien Lifehouse and Princess Alexandra Hospital.
SARC032 is the first completed randomised clinical trial of its kind and has demonstrated compelling evidence to integrate immunotherapy, with the standard treatment regimen of radiotherapy and surgery for patients with grade 2 or 3, stage III soft tissue sarcoma of the limb.
Professor Angela Hong, Australia’s Principal Investigator for the trial, believes these results will be beneficial for patients for this specific stage of sarcoma.
“This is a significant milestone. The integration of immunotherapy into standard treatment protocols heralds a new era in sarcoma management, offering patients and clinicians a potent tool in the battle against this formidable disease.”
You Might also like
-
Concerning increases in Non-Alcoholic Fatty Liver Disease and colorectal cancer
Dr Kieran Longley is a Gastroenterologist and Hepatologist committed to providing comprehensive, patient-centred care across a broad spectrum of digestive and liver conditions. He completed his medical degree at the University of Tasmania before undertaking physician training at St Vincent’s Hospital Sydney. Furthering his academic and clinical expertise, he obtained a Master of Science in Internal Medicine from the University of Edinburgh.
-
Delivering anaesthetic services to countries where surgical services can’t be provided
Dr Wendy Falloon is an Anaesthetist of over 30 years experience and a Fellow of Australian and New Zealand College of Anaesthetists (ANZCA). She studied medicine at the University of Tasmania, and worked in Hobart, Sydney and the Uk while completing her specialist qualifications. Her primary professional focus has always been to deliver the best possible experience of anaesthesia to each and every patient, and for them to know that she sees and values them, and their stories.
Having been born in Africa, she realised even as a child that health and wealth were largely a product of where people happen to be born. This sowed the seed of her ongoing desire to be of help to others in less fortunate circumstances, ultimately leading to her volunteer work with the Mercy Ships charity. This is one of the most fulfilling aspects of her career, and she has volunteered in Africa with Mercy Ships 8 times since 2014.
-
Specialist physiotherapist successfully mixes online & in-person
Dr. Kieran Richardson (FACP) is a Specialist Physiotherapist, conferred by the Australian College of Physiotherapists (Australian Physiotherapy Association) in 2016. Dr Richardson is the Director of Global Specialist Physiotherapy, a consultancy company providing online Formal Mentoring and Professional Development individual clinicians, clinics, and groups, as well as Second Opinions to clinicians and directly to patients all around the world.